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Abstract
Introduction. Anti-TNF treatment has transformed the treatment of chronic inflammatory rheumatism. Although
the therapy can be highly effective, anti-TNF drugs are associated with an increased risk of tuberculosis,
especially extra-pulmonary tuberculosis.
Laryngeal tuberculosis is rare and its symptoms are not specific. Laryngeal tuberculosis is often secondary to
another localization, particularly pulmonary. In the use of anti-TNF therapy, its development is unusual.
Case report. We report a case of bifocal tuberculosis: laryngeal and pulmonary tuberculosis revealed by
laryngeal involvement in a patient aged 41 years with axial spondylarthritis treated with Adalimumab.
Conclusion. This presentation highlights the importance to consider the rare possibility of laryngeal tuberculosis
in the presence of atypical otorhinolaryngologic signs under anti-TNF therapy and underlines the importance of
looking for other tuberculosis involvement.
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Introduction
Anti-TNF drugs have improved the management of chronic
inflammatory rheumatic diseases. However, they are not de-
void of side effects, particularly infectious ones. Indeed, anti-
TNF drugs can reactivate latent tuberculosis, especially extra-
pulmonary tuberculosis. This risk is particularly increased
with Infliximab and Adalimumab [1].
Laryngeal tuberculosis is rare and rarely primitive. It
is often secondary to primary pulmonary localization. Its
clinical presentation is often variable and not specific [2]. It
should be suspected systematically when there are atypical
otorhinolaryngologic symptoms under anti-TNF treatment.
The interest of this observation is to point out to the excep-
tional localization of tuberculosis in patients under anti-TNF
drugs.
We report the original observation of bifocal laryngeal
and pulmonary tuberculosis revealed by sore throat in a pa-
tient followed for spondylarthritis (SpA) under the use of
Adalimumab.
Observation
Mr. H.A., 41 years old, non-smoker and non-alcoholic male
patient, followed for 13 years for a severe axial SpA compli-
cated by bilateral coxitis that required a double hip replace-
ment surgery (double total hip replacement). Biotherapy with
Etanercept (50 mg/week) was indicated due to the severity
of the osteoarticular damage and the resistance to different
families of non-steroidal anti-inflammatory drugs. All screen-
ing tuberculosis tests were normal, therefore Etanercept was
initiated in 2014 without anti-tuberculous chemoprophylaxis.
A switch to Adalimumab (40mg/15 days) was decided in
2019 since an anterior uveitis of the left eye had developed in
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the patient.
After 3 months of the introduction of Adalimumab, the pa-
tient was presented with sore throat, episodes of dyspho-
nia and progressive difficulty in deglutition despite 2 weeks
course of antibiotic and high dose of corticosteroids. The pa-
tient complained of weight loss of at least 10% in just 3
months. There were no chest or osteoarticular signs. He did
not report any known contact with a case of active tuberculo-
sis.
On examination, the patient was afebrile, looked thin with
body mass index: 15.64 Kg/m2. There were no evident cer-
vical Lymphadenopathies. Physical examination of the chest
was normal.
Laboratory tests revealed inflammation with C-reactive
protein (CRP) at 36.1 mg/L, erythrocyte sedimentation rate
at 35 mm with persistent lymphopenia 1100/µl. Serum and
urine calcium were normal. Viral serology (Epstein Bar virus,
cytomegalovirus and human immunodeficiency virus) was
negative. A chest X-ray was performed, revealing a normal
aspect.
Both sputum microscopy for acid fast bacillus, and Quan-
tiferon test were negative. Serum angiotensin converting en-
zyme was normal.
Fiberoptic nasopharyngolaryngoscopy revealed a supra-
glottic edema (Fig. 1) confirmed by cervical computed tomog-
raphy scan (Fig. 2).
Figure 1. Laryngeal endoscopy showing a supraglottic
oedema and nodular mucosa without salivary stasis or lesions
suspicious of malignancy (screenshot of live laryngoscopy).
As malignancy was suspected, a laryngeal biopsy was
performed. Histology revealed no malignancy but giganto-
cellular and epithelioid granulomas without caseous necrosis.
Eso-gastrointestinal endoscopy was normal.
We’ve completed with thoracic computed tomography
(Fig. 3), which showed a focal pulmonary condensation and
micronodular infiltration. A bronchoscopy demonstrated a la-
ryngeal translucent granules and inflammatory lesions of
the right bronchus. GeneXpert test on the Bronchoalveo-
lar lavage fluid was negative. Histological examination of
the bronchial biopsy showed non-specific fibro-inflammatory
lesions with no tumor lesion.
The sputum microbiological culture revealed mycobac-
terium tuberculosis 4 weeks later. Hence, final diagnosis was
Figure 2. Cervical computed tomography showing diffuse
supraglottic laryngeal edema.
Figure 3. Thoracic computed tomography showing
branching condensation surrounded by a frosted glass area
and a micronodular infiltrate of the right middle pulmonary
lobe.
bifocal laryngeal and pulmonary tuberculosis under Adali-
mumab. Adalimumab was stopped and Chemotherapy was ini-
tiated, including: 2-months of quadruple therapy: rifampicin,
isoniazid, pyrazinamide and ethambutol, followed by 7 months
of rifampicin and isoniazid bi-therapy.
On follow up, there were complete resolution of clini-
Bifocal Tuberculosis with Adalimumab Revealed by Laryngeal Involvement: Case Report — 3/5
cal symptoms (complete clearing of dysphagia, dysphonia
and sore throat), and normalization of the biological tests (in-
flammation and lymphopenia). All lesions were cleared in
the otorhinolaryngologic control (Fig. 4), bacilloscopic con-
trol of sputum was negative and pulmonary lesions subsided
(Fig. 5).
Figure 4. Laryngeal endoscopic control after 4 months of
the anti-tubercular treatment. Supraglottic oedema and
nodular mucosa had disappeared (screenshot of live
laryngoscopy).
Figure 5. Control thoracic computed tomography after 4
months of the anti-tubercular treatment. Condensation and
frosted glass area of the middle pulmonary lobe had
disappeared.
Discussion
Anti-TNF drugs constitute a breakthrough in the treatment
of SpA. Although their efficacy, they are associated with
the serious risk of developing infectious tuberculosis [1].
Anti-TNF therapy interferes negatively with the forma-
tion and the maintenance of tuberculosis granuloma, facili-
tating the reactivation of tuberculosis [3]. More than 50%
of tuberculosis cases developed under anti-TNF therapy, are
extra-pulmonary ones [4].
The introduction of latent tuberculosis screening proce-
dures is necessary before starting anti-TNF therapy. However,
tuberculosis developed under anti-TNF drugs can still occur
despite a negative initial screen [5, 6].
Indeed, tuberculosis in patients receiving anti TNF-therapy
usually arises from the reactivation of latent infection and oc-
curs often within the first three to eight months. Nevertheless,
many cases of new tuberculosis infection under anti-TNF
drugs have been reported [7].
Quantiferon test is more specific than tuberculin tests in
screening for pulmonary tuberculosis. However, false neg-
atives and false positives have been described especially in
immunosuppressed patients [3].
GeneXpert is recommended by the World Health Orga-
nization in the pulmonary and extra-pulmonary tuberculosis
diagnosis in both immunocompetent and immunocompro-
mised patients [8, 9]. It is a rapid molecular test with high
performance (sensitivity and specificity) [10]. Multiple gen-
eXpert testing on bronchoalveolar lavage fluid can improve
the test sensitivity [9].
Laryngeal tuberculosis is observed very rarely (0.5-2%
of patients with tuberculosis), usually with immunocompro-
mised diseases. It is the most common granulomatous disease
of the larynx and represents less than 1% of all forms of
tuberculosis [11, 12].
Laryngeal tuberculosis is often secondary to bronchogenic,
hematogenous or lymphatic dissemination [13]. Laryngeal
involvement has been observed in 15 to 37% of pulmonary
tuberculosis cases, but primary involvement has been observed
in only in 19% of tuberculosis cases [14]. There are only a few
isolated cases in the literature [15].
Several sites may be affected: vocal cords (50-70%), false
vocal cords (40-50%), epiglottis, subglottic region, and pos-
terior commissure (10-15%). Symptoms of laryngeal tuber-
culosis are dysphonia, hoarseness, wasting, dysphagia and
odynophagia [11–16].
The lesions seen on laryngoscopy may be granulomatous,
edematous, ulcerative, polyploid or non-specific [15, 16].
In immunocompromised patients, laryngeal tuberculosis
could be confirmed in patients with chronic granulomatous in-
flammatory exudates and a complete recovery under antituber-
cular therapy even without the presence of caseation [16–19].
However, the absence of caseous necrosis raises diagnostic
difficulties and can be easily confused clinically with laryn-
geal cancer and other granulomatosis. A biopsy is mandatory
for a definitive diagnosis. Under antitubercular treatment,
the clinical signs of laryngeal tuberculosis disappear within
a few weeks [16].
A long-term follow-up is necessary since the laryngeal
complications can occur [12].
Bifocal pulmonary and laryngeal tuberculosis under anti-
TNF therapy is exceptional. The literature review reports
only one case developed under Adalimumab in ulcerated coli-
tis [20].
Conclusions
Laryngeal tuberculosis under anti-TNF therapy is rare, its
clinical signs are non-specific. It is often associated with
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pulmonary involvement. Thus, the suspicion of laryngeal tu-
berculosis requires the search for a pulmonary involvement.
Our case is an unusual form of bifocal laryngeal and pul-
monary tuberculosis under anti-TNF treatment revealed by
laryngeal involvement.
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